
    
      It is a double-blind, randomized, placebo control study that evaluated the action of a
      probiotic in relation to a placebo in the human intestinal microbiome by the technique of
      metagenomics, as well as evaluated the effects of this probiotic on the gastrointestinal
      transit of constipated participants.

      One hundred and twenty constipated patients will be randomized into two groups:Probiatop or
      Placebo. The first 22 patients from each group will also perform a metagenomic evaluation
      through the stool sample collection before and after of treatment. Besides these procedures,
      all patients will fill out a symptom assessment questionnaire at baseline of the study, and
      then after 14 and 28 days after the beginning of the treatment.
    
  